中文摘要：

[目的]验证多糖-硒化多糖复方的增强免疫活性,筛选出活性最强的复方,为研制新型免疫增强剂提供试验依据。[方法]在前期研究筛选出增强免疫活性较强的当归多糖（CAP）、党参多糖（CPP）、大蒜多糖（GP）、硒化当归多糖（sCAP）、硒化党参多糖（sCPP）和硒化大蒜多糖（s GP）的基础上,以其为组分药,按照多糖与硒化多糖质量比9∶1的比例组成CAP-sCPP、CAP-s GP、CPP-sCAP、CPP-s GP、GP-sCAP和GP-sCPP共6个复方,比较它们的体内/外增强免疫活性能力。体外试验,用MTT法测定6个复方对鸡外周血淋巴细胞增殖的影响;体内试验,进一步比较了筛选出的3个复方对新城疫苗免疫雏鸡淋巴细胞增殖,血清抗体效价,IL-2、IL-6和IFN-γ含量的影响。[结果]体外试验结果显示：单独或与植物血凝素（PHA）共同刺激时,6个复方均有不同程度的增强免疫活性,CAP-sCPP、GP-sCPP和CPP-sCAP的活性较强;体内试验结果显示：在免疫后7、14、21和28 d,GP-sCPP高剂量促进T淋巴细胞增殖的作用最强,血清抗体效价和IL-2、IL-6及IFN-γ含量均为最高,且均显著高于免疫对照组。[结论]GP-sCPP的增强免疫活性最强,可以考虑作为新型免疫增强剂的候选方。

英文摘要：

[ Objectives ] In order to validate the immune-enhancing activity of polysaccharide-selenizing polysaccharide compounds, a compound with the strongest activity was selected and offer theoretical evidence for developing new-type immunopotentiators was offered. [Methods] On the basis of screening out the Chinese angelica polysaccharide （CAP）, Codonopsis pilosula polysaccharide （ CPP ） , garlic polysaccharide （ GP ） , selenizing CAP （ sCAP ） , selenizing CPP （ sCPP ） and selenizing GP （sGP） with stronger immune- enhancing activity in previous research, six polysaceharide-selenizing polysaccharide compounds, CAP-sCPP, CAP-sGP, CPP-sCAP, CPP-sGP, GP-sCAP and GP-sCPP, were composed by taking them as constituents according to 9 ： 1 ratio of polysaccharide to selenizing polysaceharide, and their immune-enhancing activities in vitro and in vivo were compared. In vitro test, the effects of 6 compounds on chicken peripheral lymphocyte proliferation were determined by MTT method. In vivo test, the effects of 3 compounds screened on lymphocyte proliferation, serum antibody titer, IL-2, IL-6 and IFN-γ contents were further compared in chickens vaccinated with Newcastle disease virus vaccine. [ Results ] The results in vitro test showed that in single or synergistic stimulation with phytohemagglutinin （PHA）, all of six compounds possessed the immune-enhancing activities at different strength, and the activities of CAP-sCPP,GP-sCPP and CPP-sCAP were stronger. The resuhs in vivo test showed that in GP-sCPP at high dose group, the actions of promoting T lymphocyte proliferation were strongest, and the serum antibody titer, IL-2, IL-6 and IFN-γ contents were the highest and significantly higher than those in vaccination control group at four time points after vaccination. [ Conclusions] GP-sCPP possesses the strongest immune-enhancing activity and can be considered as a candidate of new-type immu- nopotentiators.